{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T05:49:56Z","timestamp":1792907396637,"version":"4.5.0"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nitric Oxide"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.niox.2026.02.005","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T07:44:54Z","timestamp":1772264694000},"page":"25-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["The role of nitric oxide in inflammation, tumor microenvironment, and cancer therapy"],"prefix":"10.1016","volume":"162","author":[{"given":"Akhil","family":"Nair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harishkumar","family":"Madhyastha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.C.","family":"Revanasiddappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasudev","family":"Pai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dileep","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.K.","family":"Neenu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavithra Pradeep","family":"Prabhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.niox.2026.02.005_bib1","doi-asserted-by":"crossref","first-page":"11298","DOI":"10.1073\/pnas.1812704115","article-title":"Alterations of tumor microenvironment by nitric oxide impedes castration-resistant prostate cancer growth","volume":"115","author":"Arora","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.niox.2026.02.005_bib2","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1089\/ars.2018.7527","article-title":"Molecular mechanisms of nitric oxide in cancer progression, signal transduction, and metabolism","volume":"30","author":"Somasundaram","year":"2019","journal-title":"Antioxidants Redox Signal."},{"key":"10.1016\/j.niox.2026.02.005_bib3","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3934\/Neuroscience.2019.3.104","article-title":"Interaction between hydrogen sulfide, nitric oxide, and carbon monoxide pathways in the bovine isolated retina","volume":"6","author":"Kulkarni-Chitnis","year":"2019","journal-title":"AIMSN"},{"key":"10.1016\/j.niox.2026.02.005_bib4","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.3390\/molecules30132802","article-title":"The role of nitric oxide in cancer treatment: ally or foe?","volume":"30","author":"My\u015bliwiec","year":"2025","journal-title":"Molecules"},{"key":"10.1016\/j.niox.2026.02.005_bib5","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3390\/vaccines9020094","article-title":"Current advances of nitric oxide in cancer and anticancer therapeutics","volume":"9","author":"Mintz","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.niox.2026.02.005_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/mmr.2022.12749","article-title":"Gasotransmitters in the tumor microenvironment: Impacts on cancer chemotherapy (Review)","volume":"26","author":"Salihi","year":"2022","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.niox.2026.02.005_bib7","author":"Cai"},{"key":"10.1016\/j.niox.2026.02.005_bib8","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-025-02167-1","article-title":"Cancer chemoprevention: signaling pathways and strategic approaches","volume":"10","author":"Ren","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.niox.2026.02.005_bib9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.niox.2024.08.002","article-title":"NO- and H2S- releasing nanomaterials: a crosstalk signaling pathway in cancer","volume":"151","author":"dos Reis","year":"2024","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.niox.2026.02.005_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.arres.2025.100139","article-title":"The immunologic and stromal functions of nitric oxide in fibrotic tumor microenvironments: a mini-review","volume":"17","author":"Sasse","year":"2025","journal-title":"Adv. Redox Res."},{"key":"10.1016\/j.niox.2026.02.005_bib11","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.apsb.2022.11.016","article-title":"Recent advances in diverse nanosystems for nitric oxide delivery in cancer therapy","volume":"13","author":"Gao","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.niox.2026.02.005_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108502","article-title":"The triple crown: NO, CO, and H2S in cancer cell biology","volume":"249","author":"Oza","year":"2023","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.niox.2026.02.005_bib13","doi-asserted-by":"crossref","DOI":"10.1080\/13510002.2025.2564593","article-title":"Recent advances in the investigation of the regulatory network underlying reactive nitrogen species-mediated tumorigenesis: molecular mechanisms and targeted therapeutic strategies","volume":"30","author":"Wu","year":"2025","journal-title":"Redox Rep."},{"key":"10.1016\/j.niox.2026.02.005_bib14","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1158\/1078-0432.CCR-22-2791","article-title":"Targeting nitric oxide: say NO to metastasis","volume":"29","author":"Reddy","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.niox.2026.02.005_bib15","first-page":"143","volume":"1277","author":"Vedenko","year":"2020"},{"key":"10.1016\/j.niox.2026.02.005_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216931","article-title":"Unveiling the significance of inducible nitric oxide synthase: its impact on cancer progression and clinical implications","volume":"592","author":"Chen","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.niox.2026.02.005_bib17","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1111\/bph.13815","article-title":"Nitric oxide and hydrogen sulfide: the gasotransmitter paradigm of the vascular system","volume":"174","author":"Cirino","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.niox.2026.02.005_bib18","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","article-title":"Inflammation and tumor progression: signaling pathways and targeted intervention","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.niox.2026.02.005_bib19","first-page":"281","article-title":"Aberrant signaling pathways in cancer cells: application of nanomaterials","volume":"2","author":"Roy","year":"2021","journal-title":"J Cell Signal"},{"key":"10.1016\/j.niox.2026.02.005_bib20","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.molcel.2022.12.023","article-title":"p53 engages the cGAS\/STING cytosolic DNA sensing pathway for tumor suppression","volume":"83","author":"Ghosh","year":"2023","journal-title":"Mol. Cell"},{"key":"10.1016\/j.niox.2026.02.005_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2022.102350","article-title":"Nitric oxide favours tumour-promoting inflammation through mitochondria-dependent and -independent actions on macrophages","volume":"54","author":"Drehmer","year":"2022","journal-title":"Redox Biol."},{"key":"10.1016\/j.niox.2026.02.005_bib22","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.3390\/cells10102655","article-title":"Regulation of T cells in cancer by nitric oxide","volume":"10","author":"Navasardyan","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.niox.2026.02.005_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116930","article-title":"Macrophage polarization in the tumor microenvironment: emerging roles and therapeutic potentials","volume":"177","author":"Zhang","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.niox.2026.02.005_bib24","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1172\/JCI80005","article-title":"Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected","volume":"125","author":"Marvel","year":"2015","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.niox.2026.02.005_bib25","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.4049\/jimmunol.1103553","article-title":"Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release","volume":"188","author":"Jayaraman","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.niox.2026.02.005_bib26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0213-9626(11)70015-4","article-title":"Myeloid-derived suppressor cells (MDSC): another player in the orchestra","volume":"30","author":"Gimeno","year":"2011","journal-title":"Inmunologia"},{"key":"10.1016\/j.niox.2026.02.005_bib27","author":"Ghosh"},{"key":"10.1016\/j.niox.2026.02.005_bib28","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41417-025-00886-9","article-title":"MDSC checkpoint blockade therapy: a new breakthrough point overcoming immunosuppression in cancer immunotherapy","volume":"32","author":"Ibrahim","year":"2025","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.niox.2026.02.005_bib29","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.7150\/ijbs.41653","article-title":"Downregulation of nitric oxide collaborated with radiotherapy to promote anti-tumor immune response via inducing CD8+ T cell infiltration","volume":"16","author":"Xu","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.niox.2026.02.005_bib30","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1124\/pharmrev.121.000500","article-title":"Opportunities for nitric oxide in potentiating cancer immunotherapy","volume":"74","author":"Kim","year":"2022","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.niox.2026.02.005_bib31","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0213-9626(08)70058-1","article-title":"The role of nitric oxide in the regulation of adaptive immune responses","volume":"27","author":"Ibiza","year":"2008","journal-title":"Inmunologia"},{"key":"10.1016\/j.niox.2026.02.005_bib32","unstructured":"MDSC-mediated mechanisms of immunosuppression, Www.Rndsystems.Com (n.d.). https:\/\/www.rndsystems.com\/pathways\/mdsc-mediated-mechanisms-of-immunosuppression (accessed November 27, 2025)."},{"key":"10.1016\/j.niox.2026.02.005_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117590","article-title":"Targeted modulation of myeloid-derived suppressor cells in the tumor microenvironment: implications for cancer therapy","volume":"180","author":"Qi","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.niox.2026.02.005_bib34","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1021\/acsptsci.3c00014","article-title":"Fluorescent detection of peroxynitrite produced by myeloid-derived suppressor cells in cancer and inhibition by dasatinib","volume":"6","author":"Carlson","year":"2023","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.niox.2026.02.005_bib35","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41419-025-07544-w","article-title":"Regulatory T cells in solid tumor immunotherapy: effect, mechanism and clinical application","volume":"16","author":"Pan","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.niox.2026.02.005_bib36","article-title":"Targeting myeloid-derived suppressor cells in tumor immunotherapy: current, future and beyond","volume":"14","author":"Zhao","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.niox.2026.02.005_bib37","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S1567-5769(01)00095-9","article-title":"Natural killer cells and nitric oxide","volume":"1","year":"2001","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.niox.2026.02.005_bib38","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","article-title":"Macrophages in immunoregulation and therapeutics","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.niox.2026.02.005_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.583084","article-title":"Tumor-associated macrophages in tumor immunity","volume":"11","author":"Pan","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.niox.2026.02.005_bib40","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1158\/1078-0432.CCR-17-0691","article-title":"Nitric oxide production by myeloid-derived suppressor cells plays a role in impairing Fc receptor\u2013mediated natural killer cell function","volume":"24","author":"Stiff","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.niox.2026.02.005_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.imlet.2024.106839","article-title":"In adult X-CGD patients, regulatory T cells are expanded while activated T cells display a NOX2-independent ROS increase","volume":"266","author":"Cammarata","year":"2024","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.niox.2026.02.005_bib42","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-01866-3","article-title":"S-1-Propenylcysteine promotes IL-10-induced M2c macrophage polarization through prolonged activation of IL-10R\/STAT3 signaling","volume":"11","author":"Miki","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.niox.2026.02.005_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106432","article-title":"RBM4 regulates M1 macrophages polarization through targeting STAT1-mediated glycolysis","volume":"83","author":"Huangfu","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.niox.2026.02.005_bib44","article-title":"Macrophages in tumor microenvironments and the progression of tumors","volume":"2012","author":"Hao","year":"2012","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.niox.2026.02.005_bib45","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3109\/08820139.2012.680634","article-title":"Metabolism of L-Arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives","volume":"41","author":"Raber","year":"2012","journal-title":"Immunol. Investig."},{"key":"10.1016\/j.niox.2026.02.005_bib46","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41416-018-0333-1","article-title":"Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression","volume":"120","author":"Groth","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.niox.2026.02.005_bib47","article-title":"Tumor-associated CD8+T cell tolerance induced by erythroid progenitor cells","volume":"15","author":"Fan","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.niox.2026.02.005_bib48","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.ccell.2022.09.001","article-title":"Peroxynitrite in the tumor microenvironment changes the profile of antigens allowing escape from cancer immunotherapy","volume":"40","author":"Tcyganov","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.niox.2026.02.005_bib49","doi-asserted-by":"crossref","first-page":"15478","DOI":"10.1073\/pnas.0703725104","article-title":"Nitric oxide induces CD4+CD25+ Foxp3\u2212 regulatory T cells from CD4+CD25\u2212 T cells via p53, IL-2, and OX40","volume":"104","author":"Niedbala","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.niox.2026.02.005_bib50","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1600-065X.2011.01018.x","article-title":"Regulatory T cells and Foxp3","volume":"241","author":"Rudensky","year":"2011","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.niox.2026.02.005_bib51","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3390\/antiox8090407","article-title":"Nitric oxide-mediated enhancement and reversal of resistance of anticancer therapies","volume":"8","author":"Hays","year":"2019","journal-title":"Antioxidants"},{"key":"10.1016\/j.niox.2026.02.005_bib52","doi-asserted-by":"crossref","first-page":"4600","DOI":"10.3390\/ijms22094600","article-title":"S-Nitrosylation in tumor microenvironment","volume":"22","author":"Sharma","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.niox.2026.02.005_bib53","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41419-025-08201-y","article-title":"S-nitrosylation of IRF7 induced by NOS1 expression in melanoma suppresses anti-tumor immunity","volume":"17","author":"Dai","year":"2026","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.niox.2026.02.005_bib54","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.bbrc.2015.06.082","article-title":"Bradykinin increased the permeability of BTB via NOS\/NO\/ZONAB-mediating down-regulation of claudin-5 and occludin","volume":"464","author":"Liu","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.niox.2026.02.005_bib55","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ydbio.2012.10.020","article-title":"VEGF-Mediated phosphorylation of eNOS regulates angioblast and embryonic endothelial cell proliferation","volume":"373","author":"Gentile","year":"2013","journal-title":"Dev. Biol."},{"key":"10.1016\/j.niox.2026.02.005_bib56","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.abb.2008.11.027","article-title":"Nitric oxide and airway epithelial barrier function: regulation of tight junction proteins and epithelial permeability","volume":"484","author":"Olson","year":"2009","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.niox.2026.02.005_bib57","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/sj.bjp.0704956","article-title":"Immediate and delayed VEGF-mediated NO synthesis in endothelial cells: role of PI3K, PKC and PLC pathways","volume":"137","author":"G\u00e9linas","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.niox.2026.02.005_bib58","article-title":"VEGF signaling: role in angiogenesis and beyond","volume":"1879","author":"Shaw","year":"2024","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.niox.2026.02.005_bib59","doi-asserted-by":"crossref","first-page":"6901","DOI":"10.2147\/OTT.S172042","article-title":"Targeting VEGF pathway to normalize the vasculature: an emerging insight in cancer therapy","volume":"11","author":"Wu","year":"2018","journal-title":"OTT"},{"key":"10.1016\/j.niox.2026.02.005_bib60","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006486","article-title":"Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease","volume":"2","author":"Goel","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.niox.2026.02.005_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101710","article-title":"Low-dose radiotherapy effects the progression of anti-tumor response","volume":"35","author":"Gao","year":"2023","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.niox.2026.02.005_bib62","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ccr.2013.09.014","article-title":"Low-dose irradiation programs macrophage differentiation to an iNOS+\/M1 phenotype that orchestrates effective T cell immunotherapy","volume":"24","author":"Klug","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.niox.2026.02.005_bib63","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nm1730","article-title":"Perivascular nitric oxide gradients normalize tumor vasculature","volume":"14","author":"Kashiwagi","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.niox.2026.02.005_bib64","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1158\/1078-0432.CCR-05-2257","article-title":"Roles of nitric oxide synthase inhibition and vascular endothelial growth factor Receptor-2 inhibition on vascular morphology and function in an in vivo model of pancreatic cancer","volume":"12","author":"Camp","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.niox.2026.02.005_bib65","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1182\/blood-2009-03-213629","article-title":"Low-dose radiation augments vasculogenesis signaling through HIF-1\u2013dependent and \u2013independent SDF-1 induction","volume":"116","author":"Lerman","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.niox.2026.02.005_bib66","article-title":"The potential of vascular normalization for sensitization to radiotherapy","volume":"10","author":"Guo","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.niox.2026.02.005_bib67","first-page":"198","article-title":"Intelligent polymeric hydrogen sulfide delivery systems for therapeutic applications","volume":"19","author":"Rong","year":"2023","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.niox.2026.02.005_bib68","article-title":"A nitric oxide and hydrogen sulfide dual-donating nanosystem for highly synergistic gas-radiotherapy against hepatocellular carcinoma","volume":"144","author":"Fu","year":"2023","journal-title":"Biomater. Adv."},{"key":"10.1016\/j.niox.2026.02.005_bib69","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jconrel.2023.08.038","article-title":"Nitric oxide-driven nanotherapeutics for cancer treatment","volume":"362","author":"Zhao","year":"2023","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.niox.2026.02.005_bib70","doi-asserted-by":"crossref","first-page":"7771","DOI":"10.2147\/IJN.S187089","article-title":"Nitric oxide-releasing nanoparticles improve doxorubicin anticancer activity","volume":"13","author":"Alimoradi","year":"2018","journal-title":"IJN"},{"key":"10.1016\/j.niox.2026.02.005_bib71","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.niox.2026.02.005_bib72","doi-asserted-by":"crossref","first-page":"187","DOI":"10.37349\/etat.2024.00212","article-title":"Novel therapeutic strategies targeting myeloid-derived suppressor cell immunosuppressive mechanisms for cancer treatment","volume":"5","author":"Jou","year":"2024","journal-title":"Explor Target Antitumor Ther."},{"key":"10.1016\/j.niox.2026.02.005_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2019.101190","article-title":"S-nitrosothiols and H2S donors: potential chemo-therapeutic agents in cancer","volume":"27","author":"Reis","year":"2019","journal-title":"Redox Biol."},{"key":"10.1016\/j.niox.2026.02.005_bib74","doi-asserted-by":"crossref","first-page":"FSO44","DOI":"10.4155\/fso.15.44","article-title":"Nitric oxide for cancer therapy","volume":"1","author":"Huerta","year":"2015","journal-title":"Future Sci. OA"},{"key":"10.1016\/j.niox.2026.02.005_bib75","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.7150\/thno.22679","article-title":"Stimuli-responsive nanomedicines for overcoming cancer multidrug resistance","volume":"8","author":"Zhou","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.niox.2026.02.005_bib76","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1080\/21645515.2019.1571892","article-title":"PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations","volume":"15","author":"Jiang","year":"2019","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.niox.2026.02.005_bib77","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.niox.2008.04.022","article-title":"NO-donating NSAIDs and cancer: an overview with a note on whether NO is required for their action","volume":"19","author":"Rigas","year":"2008","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.niox.2026.02.005_bib78","doi-asserted-by":"crossref","first-page":"44545","DOI":"10.1021\/acsomega.3c03734","article-title":"Smart magnetic nanocarriers for codelivery of nitric oxide and doxorubicin for enhanced apoptosis in cancer cells","volume":"8","author":"Dutta","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.niox.2026.02.005_bib79","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","article-title":"Exploring treatment options in cancer: tumor treatment strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.niox.2026.02.005_bib80","first-page":"1267","article-title":"Emerging role of MDSCS as novel biomarkers and therapeutic targets for cancer immunotherapy","volume":"14","author":"Silva-Romeiro","year":"2025","journal-title":"Interpreter Transl. Train. (ITT)"},{"key":"10.1016\/j.niox.2026.02.005_bib81","article-title":"Nitric oxide-producing multiple functional nanoparticle remodeling tumor microenvironment for synergistic photodynamic immunotherapy against hypoxic tumor","author":"Xu","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.niox.2026.02.005_bib82","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.actbio.2025.01.013","article-title":"Synergistic effects of NO\/H2S gases on antibacterial, anti-inflammatory, and analgesic properties in oral ulcers using a gas-releasing nanoplatform","volume":"194","author":"Chen","year":"2025","journal-title":"Acta Biomater."},{"key":"10.1016\/j.niox.2026.02.005_bib83","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.2147\/IJN.S505636","article-title":"Aspirin in cancer therapy: pharmacology and nanotechnology advances","volume":"20","author":"Laila","year":"2025","journal-title":"IJN"},{"key":"10.1016\/j.niox.2026.02.005_bib84","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.apsb.2024.12.015","article-title":"Drug delivery systems based on mesoporous silica nanoparticles for the management of hepatic diseases","volume":"15","author":"Liu","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.niox.2026.02.005_bib85","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.7150\/thno.104190","article-title":"Hypoxia-responsive nanoparticles for fluorescence diagnosis and therapy of cancer","volume":"15","author":"Zhang","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.niox.2026.02.005_bib86","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.948405","article-title":"Immune checkpoint inhibitors for PD-1\/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer","volume":"12","author":"Mussafi","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.niox.2026.02.005_bib87","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.canlet.2020.05.032","article-title":"Hypoxia-responsive nanoparticles for tumor-targeted drug delivery","volume":"490","author":"Li","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.niox.2026.02.005_bib88","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1021\/acscentsci.1c00317","article-title":"Activity-based NIR bioluminescence probe enables discovery of diet-induced modulation of the tumor microenvironment via nitric oxide","volume":"8","author":"Yadav","year":"2022","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.niox.2026.02.005_bib89","doi-asserted-by":"crossref","first-page":"8689","DOI":"10.1021\/acs.analchem.4c00914","article-title":"Tumor microenvironment-activatable phototheranostic: leveraging nitric oxide and weak acidity as dual biomarkers for ratiometric fluorescence, photoacoustic imaging, and photothermal therapy","volume":"96","author":"Ren","year":"2024","journal-title":"Anal. Chem."},{"key":"10.1016\/j.niox.2026.02.005_bib90","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.3390\/cancers14174240","article-title":"The nitric oxide donor [Zn(PipNONO)Cl] exhibits antitumor activity through inhibition of epithelial and endothelial mesenchymal transitions","volume":"14","author":"Ciccone","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.niox.2026.02.005_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2025.169985","article-title":"A pH-responsive and nitric oxide-producing nanocarrier for targeted therapy of melanoma","volume":"525","author":"Cui","year":"2025","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.niox.2026.02.005_bib92","first-page":"1648","article-title":"Nitric oxide inhibits apoptosis downstream of cytochrome c release by nitrosylating caspase 91","volume":"62","author":"T\u00f6r\u00f6k","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.niox.2026.02.005_bib93","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002242","article-title":"Neutrophils in the era of immune checkpoint blockade","volume":"9","author":"Faget","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.niox.2026.02.005_bib94","first-page":"380","article-title":"The application of nitric oxide delivery in nanoparticle-based tumor targeting drug delivery and treatment","volume":"14","author":"Qin","year":"2019","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.niox.2026.02.005_bib95","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2147\/IJN.S504629","article-title":"Design of pH-Responsive nanomaterials based on the tumor microenvironment","volume":"20","author":"Liu","year":"2025","journal-title":"IJN"},{"key":"10.1016\/j.niox.2026.02.005_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2018.11.001","article-title":"Specific inhibition of PI3K\u03b4\/\u03b3 enhances the efficacy of anti-PD1 against osteosarcoma cancer","volume":"16","author":"Shi","year":"2019","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.niox.2026.02.005_bib97","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.610533","article-title":"Tumor microenvironment-stimuli responsive nanoparticles for anticancer therapy","volume":"7","author":"Thomas","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.niox.2026.02.005_bib98","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj5070","article-title":"A phase 1\/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer","volume":"13","author":"Chung","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.niox.2026.02.005_bib99","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.TARG-17-A202","article-title":"Abstract A202: evaluating the combination of anti-PD-1 and nitric oxide synthase inhibition therapy in 12 triple-negative breast cancer patient-derived xenografts using a human-derived immune system model","volume":"17","author":"Davila-Gonzalez","year":"2018","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.niox.2026.02.005_bib100","doi-asserted-by":"crossref","DOI":"10.1080\/14686996.2025.2538430","article-title":"Enhanced cancer immunotherapy via synergistic action of NO-Donor nanoparticles (NanoARG) and PD-1 antibody","volume":"26","author":"Mei","year":"2025","journal-title":"Sci. Technol. Adv. Mater."},{"key":"10.1016\/j.niox.2026.02.005_bib101","author":"Martinez-Paniagua"},{"key":"10.1016\/j.niox.2026.02.005_bib102","article-title":"Adoptive cell therapy for cancer: combination strategies and biomarkers","volume":"16","author":"Liu","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.niox.2026.02.005_bib103","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.semcancer.2022.12.009","article-title":"Artificial intelligence-based multi-omics analysis fuels cancer precision medicine","volume":"88","author":"He","year":"2023","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.niox.2026.02.005_bib104","doi-asserted-by":"crossref","first-page":"7560","DOI":"10.1038\/s41467-024-51980-9","article-title":"AI-powered omics-based drug pair discovery for pyroptosis therapy targeting triple-negative breast cancer","volume":"15","author":"Ouyang","year":"2024","journal-title":"Nat. Commun."}],"container-title":["Nitric Oxide"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089860326000200?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089860326000200?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T02:28:25Z","timestamp":1776392905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089860326000200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":104,"alternative-id":["S1089860326000200"],"URL":"https:\/\/doi.org\/10.1016\/j.niox.2026.02.005","relation":{},"ISSN":["1089-8603"],"issn-type":[{"value":"1089-8603","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of nitric oxide in inflammation, tumor microenvironment, and cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Nitric Oxide","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.niox.2026.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}